Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA amp |
Therapy | Copanlisib + Neratinib |
Indication/Tumor Type | cervical cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA amp | cervical cancer | sensitive | Copanlisib + Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Aliqopa (copanlisib) and Nerlynx (neratinib) synergistically inhibited viability of an PIK3CA-amplified cervical cancer cell line in culture (PMID: 31624127). | 31624127 |
PubMed Id | Reference Title | Details |
---|---|---|
(31624127) | Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. | Full reference... |